An official website of the United States government
Home
Name
Yescarta
Alternate Names
axicabtagene ciloleucel
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
NSC Number
None
Primary Site
None
Histology
Remarks
April 1, 2022 The FDA approved axicabtagene ciloleucel (Yescarta) for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy. It is not indicated for the treatment of patients with primary central nervous system lymphoma.
March 5, 2021 FDA granted accelerated approval to axicabtagene ciloleucel (Yescarta) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy
October 18, 2017: FDA granted regular approval to axicabtagene ciloleucel (YESCARTA)for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Yescarta is an autologous CAR T-cell therapy in which T cells are isolated from a patient’s blood and engineered to target the CD19 protein that is found on lymphoma cells.
March 5, 2021 FDA granted accelerated approval to axicabtagene ciloleucel (Yescarta) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy
October 18, 2017: FDA granted regular approval to axicabtagene ciloleucel (YESCARTA)for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Yescarta is an autologous CAR T-cell therapy in which T cells are isolated from a patient’s blood and engineered to target the CD19 protein that is found on lymphoma cells.
Coding
This drug should be coded
